about
Peliosis hepatis: Personal experience and literature reviewMicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocalityCan antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cellsSensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell CulturesCirculating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis.MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancerProphylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary?Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population.Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells.Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view.Hepatitis C virus recurrence after liver transplantation: a 10-year evaluation.Lifelong maintenance of composition, function and cellular/subcellular distribution of proteasomes in human liver.Profiles of cancer stem cell subpopulations in cholangiocarcinomas.High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?The role of liver resections for metastases from lung carcinomaSurgical therapy for hepatolithiasis: a Western experience.Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature.Use of vascular clamping in hepatic surgery: lessons learned from 1260 liver resections.Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer.Trends in perioperative outcome after hepatic resection: analysis of 1500 consecutive unselected cases over 20 years.The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome.Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor-recipient age-mismatch in transplants.Liver transplantation for benign hepatic tumors: a systematic review.Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor.Real-time quantitative assay for routine testing of HCV RNA in formalin-fixed, paraffin-embedded liver samples.ALPPS for primary and secondary liver tumors.CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma.A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: A suitable tool for preclinical studies.Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach.Absence of neuroinvasive disease in a liver transplant recipient who acquired West Nile virus (WNV) infection from the organ donor and who received WNV antibodies prophylactically.Successful treatment of rhinomaxillary form of mucormycosis infection after liver transplantation: a case report.Apoptotic Epitope-Specific CD8+ T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection.Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.TGF-β signaling is an effective target to impair survival and induce apoptosis of human cholangiocarcinoma cells: A study on human primary cell cultures.Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue.Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
P50
Q28084479-CB324D8F-1E06-4F38-8A16-C2DFBFEAA6EEQ28115464-7A4821CC-DD5E-49D0-BD94-580E252CCCE9Q28222514-7450E5C7-0EF8-4A2C-82FB-5872784C793BQ28283352-BC10F281-3846-4725-B539-731A042E6DDEQ28550991-9A8FE95D-F7C1-416F-834A-2A53D0673D12Q33444002-3BBEE00F-89CB-4D32-8420-D38DCB5CA1D5Q33728068-B9515EFA-37ED-4ADF-852D-FD0C1F997680Q33830734-5290470D-5809-46A1-A94E-A38883289269Q34600925-17481CF9-85C4-4970-82CA-654A8CD1F1D0Q34647028-B9B29565-5E44-422B-9DFF-FC2A4895AAFEQ34991081-59054ACE-EFD4-4DA3-9682-AAF519E08008Q35207241-C6E8888C-312A-4B31-909F-040B53E3043AQ35270256-FA212341-DFBE-4D02-9F49-D44DDEB754C3Q35284362-26A5C794-80DD-4CC5-ABE4-3B278D921FABQ35669078-0CCF585D-1A00-460E-AE25-EDC115FA55F7Q35761342-45984D65-7A27-4783-9E03-788249B28646Q36253238-40B6B7E7-4E74-4BB3-8FAF-C108CA44DE9BQ36374255-C0996D5E-9779-4FCC-A252-E001C2F88FC3Q36424876-C419867C-97DB-427A-82C7-51A4EB520075Q36642854-9726B192-3D20-45C7-920B-24C46BC882F2Q37143693-E48A7032-C58A-4E3E-8C23-C8C9792D8D67Q37233477-83B7D166-FFFB-4AA9-A1F5-51631B4232A5Q37498096-197F5196-E6DB-48AF-AA38-18BAA5BD24A4Q37557707-72F73704-8969-4E58-B734-55C833F1C8B4Q37678208-A9AA6C31-EE63-4B9C-ABB9-A454CA48D681Q37722196-48F98F9C-4B83-474E-9517-B6E7D8232D98Q38081919-FF2AC355-6D8D-48C0-8681-09952FAAC76BQ38419463-0F214E27-E183-4A38-A81C-E25C59364655Q38876201-94126F01-F15E-47A8-A911-236FB916240FQ39330183-B43584B3-ED56-42C8-A9CC-BC33E735ED89Q40094616-B80D29B8-D3F9-426D-B9E8-05FBF8C25F5CQ40171330-9C4AF540-C289-43BD-A551-1E85E63943E8Q40198016-29468946-7B37-42A7-9711-902CB10F8DA3Q40354832-D5A52CDA-D58F-47C5-8D94-FECC6AADA545Q40475986-4BE6BF44-291A-4CC6-B5DC-01B9938E8794Q40522642-D0A7F965-67E6-49FB-B101-D29DC793A448Q41544962-7236DBFC-8BB2-4ACB-BBC5-5607C8777B14Q41617837-ED123552-F418-4A61-A193-02AF443AE89DQ42222888-80B779FB-3E9E-440E-878B-8E1B3A8C77E6Q42603832-E6D511A2-DCEB-461B-B988-7AE20B13EEA5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gian Luca Grazi
@ast
Gian Luca Grazi
@en
Gian Luca Grazi
@es
Gian Luca Grazi
@nl
type
label
Gian Luca Grazi
@ast
Gian Luca Grazi
@en
Gian Luca Grazi
@es
Gian Luca Grazi
@nl
prefLabel
Gian Luca Grazi
@ast
Gian Luca Grazi
@en
Gian Luca Grazi
@es
Gian Luca Grazi
@nl
P106
P1153
13102992200
P21
P31
P496
0000-0002-3279-0313